We sat down with Haran Maheson, Vice President & Head of Oncology at Daiichi Sankyo UK, to find out more about the company’s rapid growth, their vision to transform cancer care in the UK ...
J.P. Morgan analyst Seiji Wakao maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on March 5 and set a price target of Yen4,600.00. The company’s shares closed ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug ... 5% on Tuesday after results from the company's lung cancer trials showed that its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback